Wednesday, November 17, 2021

CMS releases the Delay of Effective Date for Provision Relating to Manufacturer Reporting of Multiple Best Prices Connected to a Value Based Purchasing Arrangement; Delay of Inclusion of Territories in Definition of States and United States (CMS 2482-F2) Final Rule

 

View in browser | Distributed by Center for Medicaid and CHIP Services (CMCS)

Medicaid.gov

Today, the Centers for Medicare and Medicaid Services (CMS) release the Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements: Delay of Effective Date and Covered Outpatient Drug; Delay of Inclusion of Territories in Definition of States and United States (CMS 2482-F2) Final Rule.

This rule finalizes two policies that were previously proposed:

  • Delaying the effective date of the best price provisions related to VBP arrangements and the reporting of multiple best prices to CMS for purposes of the Medicaid Drug Rebate (MDR) program until July 1, 2022 instead of January 1, 2022;
  • Delaying the effective date of the inclusion of the five U.S. territories in the regulatory definitions of "States" and "United States" for purposes of participating the MDR until January 1, 2023 instead of April 1, 2022.

Learn more here: https://www.federalregister.gov/public-inspection/2021-25009/medicaid-program-delay-of-effective-date-for-provision-relating-to-manufacturer-reporting-of


This e-mail was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of the Centers for Medicare & Medicaid Services (410-786-5473) · 7500 Security Boulevard · Baltimore MD 21244

No comments:

Post a Comment

Most important medical advance in 100 years

Artificial Intelligence is being harnessed to create breakthrough drugs no one has ever seen before. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ...